📅 Next week, we're heading to Zeist for the NVCB Autumn Meeting! Meet our Co-founder, Gian Nutal S., at our booth or around the venue. Gian is excited to chat about 🦴 bone health, 3D cell cultures in the bone domain, and how our mineralized Bon3OID™ models can support your upcoming projects. ✨ Don’t miss Gian’s presentation on Wednesday, 06.11 during Session I! Feel free to reach out directly to arrange a meeting with him ahead of time. 👉 For more details, visit: https://lnkd.in/erQrszMY We look forward to connecting with fellow bone enthusiasts! 🤝 #BoneHealth #OrganotypicBoneModels #BoneRegeneration #BoneMetastases #RheumatoidArthritis #Osteoporosis #Osteomyelitis #OsteogenesisImperfecta #Osteosarcoma
CompagOs
Medizinische und diagnostische Labore
Pioneering Solutions to Understand, Diagnose, and Treat Bone Conditions
Info
CompagOs is bringing better bone health to all by empowering researchers to transform discoveries into clinical applications, while enabling physicians to match patients with the right treatments and support faster recovery. At the core of our mission are our biologically relevant and reproducible Bon3OID™ in vitro bone models, developed using state-of-the-art 3D bioprinting. Leveraging this technology, we are currently focused on developing a blood-based assay to detect bone metastases earlier than existing imaging methods, representing a key step toward advancing bone health. Additionally, we provide comprehensive services to academic researchers and the life sciences industry, utilizing these models for basic research, drug efficacy, and toxicity testing, with a focus on bone biology, rare bone diseases, inflammatory bone disorders, and bone oncology.
- Website
-
https://compagos.ch
Externer Link zu CompagOs
- Branche
- Medizinische und diagnostische Labore
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Zürich
- Art
- Privatunternehmen
- Spezialgebiete
- organotypic bone models, 3D bioprinting, bone biology, bone oncology, rare bone diseases, inflammatory bone diseases, personalized medicine und bone regeneration
Orte
-
Primär
Wegbeschreibung
Zürich, CH
Beschäftigte von CompagOs
-
Chris Steffi
Postdoctoral Researcher | Sciencepreneur | Co-Founder & Board Member at CompagOs | Advancing Bone Organoid Research and Personalised Medicine
-
Robert Baumann
Chief Technology Officer at CompagOs
-
Barna Gal, MD
Co-founder at CompagOs | Transforming Drug Development, Personalized Treatments and Regenerative Medicine with Bon3OID™ in vitro Models
Updates
-
🚨 Exciting Opportunity Alert! 🚨 CompagOs AG is looking for a passionate Lab Technician – Bioprinting and Diagnostics to join our innovative team in Zurich, Switzerland! Join us as we revolutionize cancer diagnostics, targeting early detection of bone metastasis. This is a unique chance to work on groundbreaking bioprinting and diagnostic technologies in a dynamic and growing startup. 💡 Position Highlights: - Support bioprinting, sample preparation, and quality control of organotypic bone models - Collaborate with the R&D team on cutting-edge 3D bioprinting processes - Work with state-of-the-art lab equipment in our Zurich facilities 📍 Location: Zurich, Switzerland 📝 Job Type: Full-Time (1-year, renewable annually) 🎯 Start Date: January 13, 2025 📄 Interested? For a full job description, see the attached PDF. Apply by sending your resume and cover letter to: robert.baumann@compagos.ch. Know someone who’d be a great fit? Tag them below or share this post! 🚀 Gian Nutal S. Chris Steffi Barna Gal, MD Robert Baumann #Hiring #LabTechnician #BiotechJobs #ZurichJobs #Bioprinting #Diagnostics #CareerOpportunity #CancerDiagnostics #InVitroBoneModels
-
✨ We will be there too! Meet our team in Zürich 🇨🇭 – let’s catch up! ✨
❗ETH Industry Day @ Open-i 📆 21-22 November 2024 💡 50 booths representing ETH Zürich spin-offs, ETH centres, and ETH research groups. 💡 Experience a cutting-edge #exhibition with interactive demonstrations and #networking opportunities in addition to high-profile speakers. 💡 Get ready for the ETH Industry Day @ Open-i. It’s your chance to connect with pioneers and learn how the latest technologies will shape the future. ❗ Register now and benefit from the 50% ETH discount: www.ethz.ch/industryday #innovation #startup #science #technology
-
-
🦴✨ Curious about how we're shaping the future of bone health? 📍 Let’s meet at ETH Zentrum Campus next Friday during Launch! Join us in making a difference by investing in our vision. Come visit our booth or schedule a meeting—we’d love to connect! 🤝 Book a meeting here --> https://lnkd.in/eDAqYBDY ETH Entrepreneur Club SICTIC #Innovation #BoneHealth #3DOrganotypicBoneModels #3R #BoneOncology #BoneMetastasis #Osteoporosis
-
-
🎉 Congrats to our Co-founder, Gian Nutal S., for securing 3rd place with his pitch on CompagOs at the Taranto Biotech Days in Italy! 🌟 Huge thanks to the organizers for inviting us! 🙏
«La Camera ha accolto di buon grado di essere partner di un evento di tale portata scientifica. Come Casa delle imprese abbiamo ospitato la competizione fra startup, provando a dare quel supporto necessario alla nascita ed allo sviluppo dell'impresa innovativa». Così Giovanni Prudenzano, componente del Consiglio camerale e Presidente dei Consulenti del Lavoro di Taranto e del CUP Taranto, che sabato, in occasione di BioShot, seconda giornata di Taranto Biotech Days, ha portato il saluto dell'Ente e del Presidente Vincenzo Cesareo. Nove le startup in gara, impegnate in diversi campi, tre le vincitrici: 1° classificato: GenoGra 2° classificato: Youth 3° classificato: CompagOs Menzione speciale per la tarantina CranioTech. «I Biotech Days rappresentano una chance importante per Taranto, dunque, per affermarsi a livello internazionale sul tema delle biotecnologie. Insieme agli altri partner, stiamo già discutendo del futuro. La questione generale - ha sottolineato Prudenzano - si coniuga poi con quella più particolare di adottare, proprio qui, in questa città così complessa, un diverso approccio all’innovazione, mettendo insieme opportunità per le imprese e necessità delle persone, scienza, salute e prospettive future per supportare una società che rapidamente invecchia e per affrontare - con l’ambizione di fermarle o addirittura sconfiggerle – le malattie croniche, neurodegenerative ed oncologiche».
-
-
-
-
-
+8
-
-
☀️🍝 Sun, pasta, pitching, and networking! ☀️🍝 Join our Co-founder Gian Nutal S. at the Taranto Biotech Days this weekend in Italy. 📊 Don’t miss the pitching session, where he'll share how we’re transforming the early detection of bone metastases, particularly in lung cancer patients, and advancing preclinical drug development using our Bon3OID™ in vitro models to bring more effective treatments to patients in the bone domain. For more details, check out the event here: https://lnkd.in/dJ8zSqes 👋 Ci vediamo lì! #Innovation #BoneHealth #OrganotypicBoneModels #PersonalizedMedicine #BoneRegeneration #BoneMetastases #LungCancer #RheumatoidArthritis #Osteoporosis #Osteomyelitis #OsteogenesisImperfecta
-
✨ Only 2 days until we arrive in Basel! ✨ Join us to meet our Co-founders: Chris Steffi, Barna Gal, MD, and Robert Baumann. 📊 Don’t miss our poster presentation on Bon3OID™-OC, our 3D organotypic model 🧬 that replicates bone remodeling—an advanced tool for testing compounds in preclinical drug development for bone-related disorders. 👋 See you in Basel! #Innovation #Partnering #3R #BoneHealth #OrganotypicBoneModels #InVitroBoneModels #RheumatoidArthritis #BoneOncology #BoneMetastases #RareBoneDiseases #BoneBiology #Osteoporosis
-
🎉 Exciting News 🎉 We’re thrilled to announce that CompagOs is now an officially registered supplier on Scientist.com, the world’s largest marketplace for life science! 🌍🔬 This new listing makes it easier for our partners to access and book our cutting-edge services with just a few clicks. 💻✨ 🔗 Explore our company profile and book our services directly here: https://lnkd.in/etFaSgMY #LifeScience #Biotech #Innovation #ScientistCom #3DInVitroBoneModels #OrganotypicBoneModels #BoneHealth
-
-
✨ Join us next week in Basel for BioTechX Europe! ✨ Our Co-founders, Chris Steffi, Barna Gal, MD, and Robert Baumann, are excited to connect with you, discuss 🦴 advancements in bone health, and explore partnerships to develop next-generation therapies. 📊 Don't miss our poster presentation, where we showcase Bon3OID™-OC, our 3D organotypic model 🧬 that mimics bone remodeling, helping to test compounds for various bone-related disorders in preclinical drug development. 👋 We look forward to seeing you there! #Innovation #Partnering #3R #BoneHealth #OrganotypicBoneModels #InVitroBoneModels #RheumatoidArthritis #BoneOncology #BoneMetastases #RareBoneDiseases #BoneBiology #Osteoporosis
-
CompagOs is growing! We are thrilled to welcome Julia Schüpfer to the team! Julia holds a BSc in Biotechnology from ZHAW and is currently pursuing a Master in Life Sciences with a specialization in Pharmaceutical Biotechnology. With her expertise in molecular, micro-, and cell biology, she will focus on optimizing the bioprinting process for our Bon3OID™ in vitro models. We are excited to welcome Julia as a valuable addition to the CompagOs team!
-